Dacryoendoscopic observation and incidence of canalicular obstruction/stenosis associated with S-1, an oral anticancer drug
- 13 March 2012
- journal article
- case report
- Published by Springer Nature in Japanese Journal of Ophthalmology
- Vol. 56 (3) , 214-218
Abstract
To report dacryoendoscopic observations and the incidence of lacrimal obstruction/stenosis associated with S-1, an oral anticancer drug. Retrospective, nonrandomized clinical trial. A total of 52 patients (41 men, 11 women; age 42–93 years) who were prescribed the anticancer drug S-1 were studied. Patients who suffered eye complaints following S-1 treatment underwent ophthalmic examination, probing and lacrimal irrigation. Patients whose tear meniscus was high or had abnormal lacrimal irrigation were evaluated by dacryoendoscopy. Overall, 5 of 52 S-1-treated patients (9.6%) experienced lacrimal passage stenosis/obstruction. One patient had punctal stenosis, and four patients had canalicular obstruction/stenosis. The onset of epiphora ranged from 2 to 8 months (4.4 ± 2.2 months, mean ± SD) after the initiation of chemotherapy. Patients receiving S-1 treatment should be evaluated for potential lacrimal disorders, particularly canalicular obstruction/stenosis. Dacryoendoscopic observation is effective for the diagnosis of this side effect.Keywords
This publication has 22 references indexed in Scilit:
- Dacryoendoscopic surgery and tube insertion in patients with common canalicular obstruction and ductal stenosis as a frequent complicationJapanese Journal of Ophthalmology, 2009
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialThe Lancet Oncology, 2008
- Nasolacrimal Duct Obstruction Classified by Dacryoendoscopy and Treated With Inferior Meatal Dacryorhinotomy. Part I: Positional Diagnosis of Primary Nasolacrimal Duct Obstruction With DacryoendoscopeAmerican Journal of Ophthalmology, 2005
- Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulatorsAnti-Cancer Drugs, 1996
- Punctal and canalicular stenosis associated with systemic fluorouracil therapyDocumenta Ophthalmologica, 1995
- Surgical treatment of punctal-canalicular fibrosis from 5-fluorouracil therapyCancer, 1985
- Punctal-Canalicular Stenosis Related to Systemic Fluorouracil TherapyArchives of Ophthalmology (1950), 1981
- Dacryoscopy.1979
- Ocular Side Effects with 5‐FluorouracilAustralian and New Zealand Journal of Medicine, 1979
- Excessive Lacrimation From Fluorouracil TreatmentJAMA, 1973